# LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy

> **NCT01380730** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 631 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **BIOLOGICAL:** Evolocumab
- **OTHER:** Placebo to Evolocumab

## Key facts

- **NCT ID:** NCT01380730
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-01
- **Primary completion:** 2012-04-05
- **Final completion:** 2012-04-05
- **Target enrollment:** 631 (ACTUAL)
- **Last updated:** 2022-11-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01380730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01380730, "LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01380730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*